Table 1.
Patient Demographics
| Characteristic | Overall | IM | PMED | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Number | 34 | 17 | 50% | 17 | 50% | |
| Age | ||||||
| Range | 26-79 | 37-79 | 26-78 | |||
| Median | 52.5 | 55 | 47 | |||
| Sex | ||||||
| Male | 26 | 76% | 11 | 65% | 15 | 88% |
| Female | 8 | 24% | 6 | 35% | 2 | 12% |
| Stage | ||||||
| IIB | 2 | 6% | 1 | 6% | 1 | 6% |
| IIC | 2 | 6% | 2 | 12% | 0 | 0% |
| III | 25 | 74% | 10 | 59% | 15 | 88% |
| IV | 5 | 15% | 4 | 24% | 1 | 6% |
| Karnofsky performance status | ||||||
| 90% | 14 | 41% | 7 | 41% | 7 | 41% |
| 100% | 20 | 59% | 10 | 59% | 10 | 59% |
| Prior therapy | ||||||
| None | 22 | 65% | 8 | 47% | 14 | 82% |
| Temozolomide | 2 | 6% | 2 | 12% | 0 | 0% |
| Radiation alone | 3 | 9% | 2 | 12% | 1 | 6% |
| Interferon alone | 4 | 12% | 3 | 18% | 1 | 6% |
| Multiple therapies | 3 | 9% | 2 | 12% | 1 | 6% |
| Radiation + IFN-α | 2 | 6% | 1 | 6% | 1 | 6% |
| IFN-α + IL-2 | 1 | 3% | 1 | 6% | 0 | 0% |